The most commonly reported adverse events (observed in greater than 5% of clinical trial participants) were nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection-site reactions, fatigue, hypersensitivity reactions, eructation, hair loss and gastroesophageal reflux disease
It does not constitute medical advice, professional diagnosis, or treatment recommendations
Dulaglutide was less studied but showed promising signs in animals, increasing beneficial bacteria like Bacteroides, Akkermansia, and Ruminococcus
This gives them, along with innovative treatments like TMS and Spravato, potential for treatment-resistant cases
For this reason we need further studies
(30, 31) Semaglutide use was associated with decreased odds of sepsis (0.0% vs